Management of Patients Using Combination Therapy With Pioglitazone and a Dipeptidyl Peptidase-4 Inhibitor: An Analysis of Initial Versus Sequential Combination Therapy

References

• . US Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2007. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2007:1–8. http://www.cdc.gov/diabetes/pubs/factsheet07.htm. Accessed March 13, 2013
   Google Scholar
• . US Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2011:1–12. http://www.cdc.gov/diabetes/pubs/estimates11.htm. Accessed March 13, 2013
   Google Scholar
• . American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care. 2013;36(4):1033–1046
   PubMed Web of Science ®Google Scholar
• . Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 2010;365(9467):1333–1346
   Google Scholar
• . Saltiel AR. New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell. 2001;104(4):517–529
   PubMed Web of Science ®Google Scholar
• . Ashcroft FM, Rorsman P. Diabetes mellitus and the β cell: the last ten years. Cell. 2012;148(6):1160–1171
   PubMed Web of Science ®Google Scholar
• . Woo V, Shestakova MV, Ørskov C, Ceriello A. Targets and tactics: the relative importance of HbA, fasting and postprandial plasma glucose levels to glycaemic control in type 2 diabetes. Int J Clin Pract. 2008;62(12):1935–1942
   PubMed Web of Science ®Google Scholar
• . Zhang X, Gregg EW, Williamson DF, . A1C level and future risk of diabetes: a systematic review. Diabetes Care. 2010;33(7):1665–1673
   PubMed Web of Science ®Google Scholar
• . American Diabetes Association. Standards of medical care in diabetes—2012. Diabetes Care. 2012;35( Suppl 1):S11–S63
   PubMed Web of Science ®Google Scholar
• . Gillett MJ. International Expert Committee report on the role of the A1C assay in the diagnosis. Diabetes Care. 2009;32(7):1327–1334
   PubMed Web of Science ®Google Scholar
• . Menzin J, Korn JR, Cohen J, . Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus. J Manag Care Pharm. 2010;16(4):264–275
   PubMed Web of Science ®Google Scholar
• . Oglesby AK, Secnik K, Barron J, Al-Zakwani I, Lage MJ. The association between diabetes related medical costs and glycemic control: a retrospective analysis. Cost Eff Resour Alloc. 2006;4(1):1
   PubMedGoogle Scholar
• . Stratton IM, Adler AI, Neil HA, . Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–412
   PubMed Web of Science ®Google Scholar
• . Shetty S, Secnik K, Oglesby AK. Relationship of glycemic control to total diabetes-related costs for managed care health plan members with type 2 diabetes. J Manag Care Pharm. 2005;11(7):559–564
   PubMedGoogle Scholar
• . Rodbard HW, Jellinger PS, Davidson JA, . AACE/ACE Consensus Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15(6):541–559
   Web of Science ®Google Scholar
• . Eizirik DL, Nathan DM, Buse JB, . Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193–203
   PubMed Web of Science ®Google Scholar
• . Colagiuri S. Optimal management of type 2 diabetes: the evidence. Diabetes Obes Metab. 2012;14( Suppl 1):3–8
   PubMed Web of Science ®Google Scholar
• . Schwartz SS. Optimizing glycemic control and minimizing the risk of hypoglycemia in patients with type 2 diabetes. Drugs Context. 2013;2013:212255
   PubMedGoogle Scholar
• . Bruderer SG, Bodmer M, Jick SS, Bader G, Schlienger RG, Meier CR. Incidence of and risk factors for severe hypoglycaemia in treated type 2 diabetes mellitus patients in the UK—a nested case-control analysis. Diabetes Obes Metab. 2014. doi:10.1111/dom.12282
   Google Scholar
• . Cheung BMY, Ong KL, Cherny SS, Sham PC, Tso AWK, Lam KSL. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med. 2009;122(5):443–453
   PubMed Web of Science ®Google Scholar
• . Fowler GC, Vasudevan DA. Type 2 diabetes mellitus: managing hemoglobin A(1c) and beyond. South Med J. 2010;103(9):911–916
   PubMed Web of Science ®Google Scholar
• . Stolar MW. Defining and achieving treatment success in patients with type 2 diabetes mellitus. Mayo Clin Proc. 2010;85 ( 12 Suppl):S50–S59
   PubMedGoogle Scholar
• . Waugh N, Cummins E, Royle P, . Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technol Assess. 2010;14(36):1–248
   Web of Science ®Google Scholar
• . Eskesen S, Kelsberg G, Hitchcock K, Lo V. Clinical inquiries. What is the role of combination therapy (insulin plus oral medication) in type 2 diabetes? J Fam Pract. 2006;55(11):1001–1003
   PubMed Web of Science ®Google Scholar
• . Poolsup N, Suksomboon N, Setwiwattanakul W. Efficacy of various antidiabetic agents as add-on treatments to metformin in type 2 diabetes mellitus: systematic review and meta-analysis. ISRN Endocrinol. 2012;2012:798146
   PubMedGoogle Scholar
• . Mikhail N. Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential. Vasc Health Risk Manag. 2008;4(6):1221–1227
   PubMedGoogle Scholar
• . Aguilar RB. Evaluating treatment algorithms for the management of patients with type 2 diabetes mellitus: a perspective on the definition of treatment success. Clin Ther. 2011;33(4):408–424
   PubMed Web of Science ®Google Scholar
• . Gross B, Staels B. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes. Best Pract Res Clin Endocrinol Metab. 2007;21(4):687–710
   PubMed Web of Science ®Google Scholar
• . Norris AW, Sigmund CD. A second chance for a PPARγ targeted therapy? Circ Res. 2012;110(1):8–11
   PubMed Web of Science ®Google Scholar
• . PPAR Research Journal. http://www.hindawi.com/journals/ppar/. Accessed March 13, 2013
   Google Scholar
• . Derosa G, Maffioli P. Dipeptidyl peptidase-4 inhibitors: 3 years of experience. Diabetes Technol Ther. 2012;14(4):350–364
   PubMed Web of Science ®Google Scholar
• . Drab SR. Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects. Pharmacotherapy. 2010;30(6):609–624
   PubMed Web of Science ®Google Scholar
• . Guthrie RM. Evolving therapeutic options for type 2 diabetes mellitus: an overview. Postgrad Med. 2012;124(6):82–89
   PubMed Web of Science ®Google Scholar
• . McIntosh B, Cameron C, Singh SR, . Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis. Open Med. 2011;5(1):e35–48
   PubMedGoogle Scholar
• . Fonseca V, Staels B, Morgan JD, . Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes. J Diabetes Complications. 2013;27(2):177–183
   PubMed Web of Science ®Google Scholar
• . Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab. 2007;9(2):166–174
   PubMed Web of Science ®Google Scholar
• . Gomis R, Espadero RM, Jones R, Woerle HJ, Dugi KA. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011;13(7):653–661
   PubMed Web of Science ®Google Scholar
• . Gomis R, Owens DR, Taskinen MR, . Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extension. Int J Clin Pract. 2012;66(8):731–740
   PubMed Web of Science ®Google Scholar
• . Pratley RE, Reusch JEB, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin. 2009;25(10):2361–2371
   PubMed Web of Science ®Google Scholar
• . Rosenstock J, Kim SW, Baron MA, . Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab. 2007;9(2):175–185
   PubMed Web of Science ®Google Scholar
• . Yoon KH, Shockey GR, Teng R, . Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes. Int J Clin Pract. 2011;65(2):154–164
   PubMed Web of Science ®Google Scholar
• . Yoon KH, Steinberg H, Teng R, . Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study. Diabetes Obes Metab. 2012;14(8):745–752
   PubMed Web of Science ®Google Scholar
• . Schernthaner G, Barnett A H, Betteridge DJ, . Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia. 2010;53(7):1258–1269
   PubMed Web of Science ®Google Scholar
• . Bennett WL, Maruthur NM, Singh S, . Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med. 2011;154(9):602–613
   PubMed Web of Science ®Google Scholar
• . Han S, Iglay K, Davies MJ, Zhang Q, Radican L. Glycemic effectiveness and medication adherence with fixed-dose combination or coadministered dual therapy of antihyperglycemic regimens: a meta-analysis. Curr Med Res Opin. 2012;28(6):969–977
   PubMed Web of Science ®Google Scholar
• . National Institute for Health and Clinical Excellence. NICE Short Clinical Guideline 87—Type 2 Diabetes: Newer Agents for Blood Glucose Control in Type 2 Diabetes. London, UK: National Institute for Health and Clinical Excellence; 2009:1–102. http://www.nice.org.uk/nicemedia/live/12165/44318/44318.pdf. Accessed March 13, 2013
   Google Scholar
• . Dormandy JA, Charbonnel B, Eckland DJA, . Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279–1289
   PubMed Web of Science ®Google Scholar
• . Henry RR, Staels B, Fonseca VA, . Efficacy and safety of initial combination treatment with sitagliptin and pioglitazone—a factorial study. Diabetes Obes Metab. 2014;16(3):223–230
   PubMed Web of Science ®Google Scholar